GSK consumer spinoff Haleon said on Thursday that it was making changes to its operating units and announced the creation of a new chief growth officer role as it evolves the operating model to ...

Fintel reports that on January 23, 2026, Barclays upgraded their outlook for Haleon plc - Depositary Receipt (NYSE:HLN) from ...

Among upgrades, Barclays lifted L’Oréal to “overweight” from “underweight” and raised its price target to €435 from €325. L’Oréal shares last closed at €385.4, implying 12.9% upside.

For those looking to find strong Consumer Discretionary stocks, it is prudent to search for companies in the group that are ...

In a report released today, Tom Sykes from Deutsche Bank reiterated a Buy rating on Haleon PLC, with a price target of p335.00. According to TipRanks, Sykes is a 3-star analyst with an average return ...

FILE PHOTO: The company logo for Haleon and the trading info is displayed on a screen on the floor of the NYSE in New York (Reuters) -Haleon is recalling some lots of its adult cough syrup Robitussin ...

Consumer health care giant Haleon plans to sell its nicotine replacement therapy (NRT) business outside of the U.S. to Dr. Reddy’s Laboratories in a deal worth $633 million. A June 26 press release ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Haleon PLC closed 11.11% below its 52-week high of £4.20, which the company reached on May 30th.

Haleon is a leading consumer healthcare company operating in the OTC medication, vitamins, minerals & supplements, and oral health segments. The company's strong brand and product moat make it less ...

Haleon sells health products internationally with stable operations and modest growth through a good performance in oral health products, and growth in Asia Pacific. The company's financials have ...

This Valentine’s Day, Haleon wants to remind men that erectile dysfunction (ED) is a common medical issue with available treatment options. An estimated quarter of American men suffer from ED, which ...